Dyne Therapeutics, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Dyne Therapeutics announced additional one-year data from the ACHIEVE Phase 1/2 trial of z-basivarsen (DYNE-101) for myotonic dystrophy type 1. A pooled dose group (N=26) showed sustained functional improvement across multiple measures at 12 months versus baseline and versus placebo; vHOT (video hand opening time) improved 3.2 seconds at 6 months (vs. +0.4 sec placebo), 5xSTS improved 1.2 seconds, 10MWR improved 0.3 seconds, QMT total improved 4.8% predicted, and MDHI total score improved 25.2% relative to baseline. The company expects registrational expansion cohort (REC, N=71) topline data in Q1 2027 to support potential U.S. Accelerated Approval application in Q3 2027; REC mean baseline vHOT is 8.3 seconds. Safety profile remained favorable with no serious drug-related adverse events.
Why this rating
Phase 1/2 data supporting accelerated approval pathway for lead candidate is material for clinical-stage biotech (~$950M cap). Positive efficacy data de-risks regulatory pathway but approval not assured; REC results critical next inflection point in Q1 2027.
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.